P 321

Drug Profile

P 321

Alternative Names: P-321; Xerophthalamia therapeutic - Parion

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Parion Sciences
  • Class Eye disorder therapies
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 02 Jun 2017 Parion Sciences terminates a phase II trial for Dry eyes in USA (NCT02824913)
  • 26 Jul 2016 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (9200230; NCT02831387)
  • 10 Jul 2016 Parion Sciences plans a phase IIb trial for Dry eyes (Opthalmic) in USA (NCT02831387)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top